For Research Use Only. Not for use in diagnostic procedures.

Sf9 insect cells using baculovirus

50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.

Store product at -70 degree C.
For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature.
For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Small volumes of PTC1 recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Description: Recombinant human RET/PTC1, the fusion protein [CCDC6 (1-101)-RET (713-end)], was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.
Scientific Background: RET/PTC1 is fused of RET and the activating CCDC6 gene by intrachromosomal paracentric inversions in chromo-some 10 (1). Likes RET/PTC3, it is the most frequent RET rearrangements in papillary thyroid carcinoma (PTC) (2), especially in radiation-induced tumours. The RET/PTC1 rearrangements may be a marker for later-occurring PTC of radiation-exposed children and *****s (3). The RET/PTC rearrangements also have been shown in benign thyroid lesions, including Hashimoto's thyroiditis (HT).

Enzymes; Active Kinase Mutants

Kinase Assay, Western Blot (WB)

~80 kDa

coiled-coil domain containing 6

coiled-coil domain-containing protein 6

Coiled-coil domain-containing protein 6

D10S170; TST1??[Similar Products]

This gene encodes a coiled-coil domain-containing protein. The encoded protein is ubiquitously expressed and may function as a tumor suppressor. A chromosomal rearrangement resulting in the expression of a fusion gene containing a portion of this gene and the intracellular kinase-encoding domain of the ret proto-oncogene is the cause of thyroid papillary carcinoma.[provided by RefSeq, Sep 2010]

CCDC6: Defects in CCDC6 are a cause of thyroid papillary carcinoma (TPC). TPC is a common tumor of the thyroid that typically arises as an irregular, solid or cystic mass from otherwise normal thyroid tissue. Papillary carcinomas are malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. A chromosomal aberration involving CCDC6 is found in thyroid papillary carcinomas. Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene.

Protein type: Apoptosis; Cytoskeletal; Oncoprotein

Chromosomal Location of Human Ortholog: 10q21.2

Cellular Component: cytosol

Molecular Function: protein binding; structural constituent of cytoskeleton

Disease: Thyroid Carcinoma, Papillary

1. Grieco M. et al: PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557-563. 2. Nikiforov YE: RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002, 13:3-16. 3. Smida J. et al: Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and *****s from Belarus. Int J Cancer 1999, 80:32-38.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.